You just read:

Jazz Pharmaceuticals Announces That Patient Enrollment is Complete for the Phase 3 Studies of JZP-110 Evaluating Excessive Sleepiness in Obstructive Sleep Apnea

News provided by

Jazz Pharmaceuticals plc

Sep 26, 2016, 16:05 ET